Penobscot Investment Management Company Inc. Purchases 10,177 Shares of Boston Scientific Corporation $BSX

Penobscot Investment Management Company Inc. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 31.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 42,607 shares of the medical equipment provider’s stock after buying an additional 10,177 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Boston Scientific were worth $4,576,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. 1248 Management LLC purchased a new stake in Boston Scientific during the 1st quarter worth about $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific in the 1st quarter worth about $27,000. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the 2nd quarter worth about $37,000. Finally, Activest Wealth Management increased its position in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $97.30 on Friday. The stock has a 50 day moving average of $102.93 and a 200 day moving average of $102.05. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The firm has a market cap of $144.17 billion, a PE ratio of 57.91, a PEG ratio of 2.32 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company earned $0.62 earnings per share. The firm’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BSX. Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Saturday, September 27th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research report on Monday, September 29th. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Finally, BTIG Research boosted their price target on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $120.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.